Summary of Medical Centers Spearhead China’s Pharma Push

Looking for the article?
We have the summary! Get the key insights in just 5 minutes.

Medical Centers Spearhead China’s Pharma Push summary
Start getting smarter:
or see our plans




China has been more of a spectator than an active participant in the global drug development arena. Its biomedical research has lacked funds and innovation, and very few results are being translated into clinical use. Science magazine’s Asia correspondent Dennis Normile looks at the problems that Chinese biomedical research has been facing and what measures Chinese authorities are putting into place to kickstart innovation. getAbstract recommends this concise and informative overview to anyone who needs or wants to know the direction Chinese biomedical research and drug development is heading.

About the Author

Dennis Normile is the Asia correspondent for Science magazine. He writes about research and science policy development, in particular in China and Japan.



​​​​​​China has lagged behind other nations in the field of biomedical research.

China’s biomedical research and its ability to translate research results into real-world applications has been floundering for a while. The first problem lies with research and development (R&D). R&D only plays a relatively small role in China’s pharma industry. Clinicians have to deal with massive patient loads and do not have much time left for non-clinical research. Academics need to publish in peer-reviewed journals at high rates. Also, the current drug review process...

More on this topic

Customers who read this summary also read

More than Medicine
When Will Clinical Trials Finally Reflect Diversity?
Daring to Hope
Small but Mighty
Dubious Diagnosis
The Alzheimer’s Gamble

Related Channels

Comment on this summary